IRIS UniCatt

Guidi, Luisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.390
EU - Europa 2.736
AS - Asia 2.344
SA - Sud America 438
AF - Africa 73
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 8.986
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.314
SG - Singapore 1.102
DE - Germania 1.014
CN - Cina 582
SE - Svezia 461
BR - Brasile 365
FR - Francia 244
UA - Ucraina 242
IT - Italia 215
VN - Vietnam 167
GB - Regno Unito 146
IE - Irlanda 130
IN - India 121
ID - Indonesia 84
FI - Finlandia 68
JP - Giappone 50
TR - Turchia 49
PL - Polonia 48
RU - Federazione Russa 48
CA - Canada 34
HK - Hong Kong 33
AR - Argentina 32
BD - Bangladesh 30
BE - Belgio 25
MX - Messico 22
ZA - Sudafrica 22
IQ - Iraq 19
ES - Italia 17
NL - Olanda 17
SA - Arabia Saudita 15
AT - Austria 14
IR - Iran 13
VE - Venezuela 12
PK - Pakistan 11
MA - Marocco 10
CI - Costa d'Avorio 9
EC - Ecuador 9
PH - Filippine 9
KR - Corea 8
CO - Colombia 7
CZ - Repubblica Ceca 7
NP - Nepal 7
TN - Tunisia 7
JM - Giamaica 6
HU - Ungheria 5
JO - Giordania 5
KE - Kenya 5
PT - Portogallo 5
UY - Uruguay 5
UZ - Uzbekistan 5
BG - Bulgaria 4
CH - Svizzera 4
DZ - Algeria 4
GR - Grecia 4
IL - Israele 4
LT - Lituania 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AO - Angola 3
CR - Costa Rica 3
EG - Egitto 3
ET - Etiopia 3
LV - Lettonia 3
OM - Oman 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
BZ - Belize 2
CG - Congo 2
CL - Cile 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
HN - Honduras 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MY - Malesia 2
PE - Perù 2
PY - Paraguay 2
TW - Taiwan 2
AQ - Antartide 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EU - Europa 1
GA - Gabon 1
GY - Guiana 1
HR - Croazia 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
MM - Myanmar 1
NI - Nicaragua 1
Totale 8.977
Salva come PNG Salva come JPEG
Città #
Singapore 621
Chandler 554
Ashburn 298
San Jose 297
Jacksonville 168
Beijing 139
Dublin 126
San Mateo 122
New York 120
Dearborn 107
Ann Arbor 101
Los Angeles 78
Jakarta 75
Nanjing 71
Lauterbourg 69
Wilmington 65
Munich 64
Cattolica 59
Nürnberg 59
Boston 55
Tokyo 45
Milan 43
Hefei 39
Ho Chi Minh City 39
Hanoi 38
Houston 37
Bremen 34
Princeton 34
Frankfurt am Main 33
Lawrence 33
Moscow 30
Izmir 28
São Paulo 28
Hong Kong 26
Seattle 25
Warsaw 25
Marseille 24
Brussels 23
Dallas 22
Lancaster 22
Buffalo 21
Fairfield 21
Kraków 21
Nanchang 20
The Dalles 19
Woodbridge 19
Redwood City 18
Guangzhou 17
Santa Clara 17
Shenyang 17
Changsha 16
Hangzhou 16
Shanghai 16
Augusta 15
Boardman 14
Helsinki 14
London 14
Rome 14
Da Nang 13
Leawood 13
Mountain View 12
Rio de Janeiro 12
Tianjin 12
Belo Horizonte 11
Brasília 11
Hebei 11
Jiaxing 11
Johannesburg 11
Nuremberg 11
Paris 11
Stockholm 11
Toronto 11
Baghdad 10
Chicago 10
Detroit 10
Hyderabad 10
Kunming 10
Pune 10
Abidjan 9
Atlanta 9
Brooklyn 9
Norwalk 9
Redmond 9
San Francisco 9
Zhengzhou 9
Ardabil 8
Costa Mesa 8
Düsseldorf 8
Turku 8
Andover 7
Ankara 7
Cagliari 7
Denver 7
Haiphong 7
Kent 7
Mexico City 7
Orem 7
University Park 7
Vienna 7
Amsterdam 6
Totale 4.577
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 367
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 219
Early atherosclerosis in patients with inflammatory bowel disease. 212
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 209
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 197
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 190
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 189
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 188
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 187
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 174
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 171
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 169
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 166
Ileal Crohn's disease: CEUS determination of activity 164
Sonography of the small bowel after oral administration of fluid: an assessment of the diagnostic value of the technique 163
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 163
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 156
Use of infliximab in particular clinical settings: management based on current evidence. 154
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 152
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 145
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 141
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 140
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 138
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 138
Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy 137
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 133
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 131
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 130
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 128
Management of perianal fistulas in Crohn's disease: an up-to-date review 127
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 127
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 126
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 123
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 121
Paradoxical arthritis occurring during anti-TNF in patients with Inflammatory Bowel Disease: histological and immunological features of a complex synovitis. 121
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 113
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 111
AID in aging and autoimmune diseases 110
Mucosal healing in ulcerative colitis: surveillance or colectomy? 110
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 107
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 106
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 105
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 104
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 104
Neuropeptide Y plasma levels and immunological changes during academic stress 102
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 101
[Soluble factors with immunosuppressive activity in human neoplasms] 100
The Italian registry of therapeutic apheresis: Granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study 97
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 97
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 94
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 93
Adalimumab in active ulcerative colitis: a "real-life" observational study 91
Linking estrogen receptor β expression with inflammatory bowel disease activity 91
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 90
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 89
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 88
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 88
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 88
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. 87
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 86
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 85
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 85
Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis 84
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 80
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 79
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 77
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. 76
Watery stools and metabolic acidosis 76
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. 75
Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: A single-centre experience 72
Serum levels of metalloproteinases and their inhibitors in nonalcoholic steatohepatitis 61
Small bowel diseases 44
Small bowel diseases 40
Totale 9.082
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.696
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.696
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021131 0 0 0 0 0 0 0 0 0 0 117 14
2021/2022646 55 45 9 107 16 14 8 116 19 27 106 124
2022/20231.376 184 193 96 233 109 159 54 115 172 10 33 18
2023/2024639 30 185 18 46 17 112 25 38 10 22 62 74
2024/20251.116 23 42 117 18 122 46 37 65 156 123 199 168
2025/20262.801 494 70 154 337 510 127 562 131 173 225 18 0
Totale 9.082